FEMY

In a report released on October 24, Jason McCarthy from Maxim Group maintained a Buy rating on Femasys (FEMY - Research Report), with a price target of $5.00. The company's shares closed today at $1.41.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Moleculin Biotech, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -42.5% and a 12.47% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Femasys with a $5.00 average price target, a 254.61% upside from current levels. In a report released on October 20, H.C.
https://www.tipranks.com/news/blurbs/femasys-femy-gets-a-buy-from-maxim-group?utm_source=advfn.com&utm_medium=referral